Q2 2014 13F Holders as of 6/30/2014
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
131
-
Total 13F shares, excl. options
-
25.4M
-
Shares change
-
+92
-
Total reported value, excl. options
-
$1.67B
-
Value change
-
-$31.6M
-
Put/Call ratio
-
0.51
-
Number of buys
-
80
-
Number of sells
-
-65
-
Price
-
$66.00
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2014
174 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2014.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 131 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.4M shares
of 49.6M outstanding shares and own 51.11% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP LLC (5.69M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.21M shares), FMR LLC (1.52M shares), VANGUARD GROUP INC (1.49M shares), LORD, ABBETT & CO. LLC (1.36M shares), FRANKLIN RESOURCES INC (763K shares), State Street Corp (651K shares), BlackRock Institutional Trust Company, N.A. (597K shares), BB Biotech AG (577K shares), and BlackRock Fund Advisors (529K shares).
This table shows the top 131 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.